ClinicalTrials.gg
CompletedNCT04598542Updated Jan 12, 2021

Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers

A Phase 1 interventional study of Lorecivivint (LOR) and Triamcinolone acetonide (TA) in Drug-Drug Interaction, sponsored by Biosplice Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-12.

Sponsored by Biosplice Therapeutics, Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Dec 2020, 5 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will be an open-label, parallel-arm study to determine if a prior intra-articular (IA) injection of lorecivivint (LOR) affects the safety, tolerability, and/or pharmacokinetics (PK) of a subsequent IA injection of the corticosteroid triamcinolone acetonide (TA) into the same knee, and to determine if a prior IA injection of TA affects the safety or tolerability of a subsequent IA injection of LOR into the same knee.

02

Conditions studied

  • Drug-Drug Interaction

Keywords

  • lorecivivint
  • triamcinolone acetonide
03

In context

Lead sponsor

Biosplice Therapeutics, Inc. is the lead sponsor of 22 studies on the registry; none are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 12 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Males and females between 18 and 55 years of age, inclusive, in general good health
  2. (BMI) ≥ 18.5 and ≤ 32.0 kg/m2 at Screening
  3. Negative drug test for amphetamine, cocaine, methadone, opiates, phencyclidine (PCP), barbiturates, benzodiazepines, tricyclic antidepressants, and marijuana

Key Exclusion Criteria:

  1. Pregnant women, breastfeeding women, and women who are not (defined as 12 months with no menses without an alternative medical cause) or permanently surgically sterile (includes hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) who have a positive or indeterminate pregnancy test result at the Screening Visit or Day -1
  2. Women who are not post-menopausal or permanently surgically sterile who are sexually active, and who are not willing to use during the study period
  3. Men who are sexually active and of , who have partners who are capable of becoming pregnant, and who are not willing to use birth control during the study period
  4. Any chronic medical condition that requires medication
  5. Any history of IA injection, surgery (e.g., arthroscopy), infection, major orthopedic injury, or inflammatory rheumatic diseases (e.g., rheumatoid arthritis, gout, pseudogout) of either knee
  6. Any for an IA injection in the right knee in the opinion of the Investigator
  7. Previous treatment with lorecivivint (LOR)
  8. Treatment with any (oral, intravenous, intramuscular, IA, topical, or inhaled) within 12 weeks before Day 1
  9. Consumption of grapefruit, grapefruit juice, Seville oranges, or vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi, brussels sprouts) within 10 days before Day 1
  10. Known to triamcinolone acetonide (TA)
  11. Significant blood loss (> 500 mL) or donation of blood within 30 days of screening
  12. Regular use of nicotine-containing products, including, but not limited to, cigarettes, e-cigarettes, or nicotine gum or patches
  13. Any condition, that, in the opinion of the Investigator, constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation
  14. Estimated (eGFR) of \< 60 mL/min/1.73 m2, calculated using the Modification of Diet in Renal Disease (MDRD) equation at the Screening Visit
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    TA injection followed by LOR injection

    IA injection of TA into the right knee, followed by IA injection of LOR into the same knee 7 days later.

    Drug: Lorecivivint (LOR) · Drug: Triamcinolone acetonide (TA)

  • Experimental
    LOR injection followed by TA injection

    IA injection of LOR into the right knee, followed by IA injection of TA into the same knee 7 days later.

    Drug: Lorecivivint (LOR) · Drug: Triamcinolone acetonide (TA)

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax of LOR

    Time frame: 0, 0.25, 0.5, 1, 2, 4, 6, 8 hours after administration

  2. AUC 0-last of LOR

    Time frame: 0, 0.25, 0.5, 1, 2, 4, 6, 8 hours after administration

  3. Plasma concentration profiles of LOR

    Time frame: 0, 0.25, 0.5, 1, 2, 4, 6, 8 hours after administration

  4. Cmax of TA

    Time frame: 0, 1, 2, 4, 6, 8, 10, 12, 24, 48, 96 hours after administration

  5. AUC 0-last of TA

    Time frame: 0, 1, 2, 4, 6, 8, 10, 12, 24, 48, 96 hours after administration

  6. Plasma concentration profiles of TA

    Time frame: 0, 1, 2, 4, 6, 8, 10, 12, 24, 48, 96 hours after administration

07

Study locations

1 site
  • Research Site
    Miami, Florida 33126, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Dec 2020, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2020
First posted
Oct 22, 2020
StartActual
Oct 13, 2020
Primary completionActual
Dec 22, 2020
CompletionActual
Dec 22, 2020
Last update
Jan 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04598542
Responsible party
Sponsor
First posted
Oct 22, 2020
Start date
Oct 13, 2020
Primary completion
Dec 22, 2020
Completion
Dec 22, 2020
Last update
Jan 12, 2021

Study contacts

Yusuf Yazici, M.D.
study director · Biosplice Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lorecivivint · Triamcinolone Acetonide

Start the discussion